Neurocrine Biosciences, Inc.

NBIX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.1%

Institutions102.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$2.86B	$2.36B	$1.89B	$1.49B	$1.13B	$1.05B	$788.09M	$451.24M	$161.63M	$15.00M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$52.10M	$34.00M	$39.70M	$23.20M	–	–	–	$4.89M	$1.25M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$619.10M	$570.50M	$250.90M	$249.00M	$102.50M	$163.00M	$72.28M	$36.90M	-$131.36M	-$147.37M
Operating income as a percentage of revenue.	21.6%	24.2%	13.3%	16.7%	9.0%	15.6%	9.2%	8.2%	-81.3%	-982.5%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$478.60M	$341.30M	$249.70M	$154.50M	$89.60M	$407.30M	$37.01M	$21.11M	-$142.54M	-$141.09M
Net income divided by the number of shares outstanding — profit attributable to each share.	$4.81	$3.40	$2.56	$1.61	$0.95	$4.38	$0.40	$0.00	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$4.67	$3.29	$2.47	$1.56	$0.92	$4.16	$0.39	$0.00	$-1.00	$-1.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$713.00M	$233.00M	$251.10M	$262.90M	$340.80M	$187.10M	$112.28M	$141.71M	$254.71M	$83.27M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$4.63B	$3.72B	$3.25B	$2.37B	$2.07B	$1.73B	$1.31B	$993.15M	$817.59M	$365.09M
All of the company's interest-bearing borrowings, short and long term combined.	–	$0	$170.10M	$169.40M	–	$0	$408.81M	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$1.38B	$1.13B	$1.02B	$660.90M	$698.50M	$608.50M	$669.12M	$512.39M	$445.45M	$50.21M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$3.25B	$2.59B	$2.23B	$1.71B	$1.37B	$1.13B	$636.92M	$480.76M	$372.14M	$314.88M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$782.70M	$595.40M	$389.90M	$339.40M	$256.50M	$228.50M	$152.05M	$101.36M	-$94.33M	-$106.18M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$34.00M	$38.20M	$28.30M	$16.50M	$23.40M	$10.90M	$14.75M	$24.81M	$6.94M	$4.11M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$748.70M	$557.20M	$361.60M	$322.90M	$233.10M	$217.60M	$137.31M	$76.55M	-$101.27M	-$110.29M

	You	Peer avg
P/E	22.8	24.0
Revenue Growth	+39.5%	+83.8%
ROE	22.1%	-8.2%

Neurocrine Biosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison